GSK's Nuvalent deal tackles HIV cliff to win cautious backing from analysts

GSK's Nuvalent deal tackles HIV cliff to win cautious backing from analysts

Summary aggregated from Yahoo Finance's public RSS feed. The full reporting belongs to Yahoo Finance — please read it on their site.